Italia markets close in 6 hours 56 minutes

Bristol-Myers Squibb Company (0R1F.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
72,70+0,20 (+0,28%)
In data: 07:03PM BST. Mercato aperto.

Bristol-Myers Squibb Company

Route 206 & Province Line Road
Princeton, NJ 08543
United States
609 252 4621
https://www.bms.com

Settore/i
Settore
Impiegati a tempo pieno34.100

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Dr. Christopher S. Boerner Ph.D.CEO & Chairman3,14MN/D1971
Mr. David V. ElkinsExecutive VP & CFO2,28MN/D1968
Ms. Sandra Leung Esq.Executive VP & General Counsel2,58MN/D1961
Mr. Samit Hirawat M.D.Executive VP, Chief Medical Officer & Head of Development2,62MN/D1969
Mr. Greg MeyersExecutive VP and Chief Digital & Technology OfficerN/DN/D1973
Mr. Timothy PowerVP & Head of Investor RelationsN/DN/DN/D
Ms. Kimberly M. JablonskiChief Compliance & Ethics OfficerN/DN/DN/D
Ms. Ahn Amanda PooleExecutive Vice President & Chief Human Resources OfficerN/DN/D1975
Dr. Joseph J. Eiden Jr.Head of Medical AffairsN/DN/D1949
Mr. Adam LenkowskyExecutive VP, Chief Commercialization Officer & Head of U.S. OncologyN/DN/D1972
Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Governance aziendale

L'ISS Governance QualityScore di Bristol-Myers Squibb Company al 1 maggio 2024 è 4. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 7; diritti degli azionisti: 2; retribuzione: 1.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.